Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Press Releases Year None202220212020 Jul 05, 2022 Adagio Announces David Hering Named Permanent Chief Executive Officer and Director Jul 01, 2022 Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors May 13, 2022 Adagio Therapeutics Reports First Quarter 2022 Financial Results Apr 14, 2022 Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request Mar 30, 2022 Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization Mar 18, 2022 Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders Feb 23, 2022 Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer Feb 22, 2022 Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates Feb 18, 2022 Adagio Therapeutics Announces CEO Succession Plan Jan 12, 2022 Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
Year None202220212020 Jul 05, 2022 Adagio Announces David Hering Named Permanent Chief Executive Officer and Director Jul 01, 2022 Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors May 13, 2022 Adagio Therapeutics Reports First Quarter 2022 Financial Results Apr 14, 2022 Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request Mar 30, 2022 Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization Mar 18, 2022 Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders Feb 23, 2022 Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer Feb 22, 2022 Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates Feb 18, 2022 Adagio Therapeutics Announces CEO Succession Plan Jan 12, 2022 Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
Jul 01, 2022 Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
Mar 30, 2022 Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
Jan 12, 2022 Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron
